Preview

Научно-практическая ревматология

Расширенный поиск

БОРЬБА С МНОГОЛИКИМ КАХЕКТИНОМ (ОПЫТ ПРИМЕНЕНИЯ ИНФЛИКСИМАБА ПО НЕЗАРЕГИСТРИРОВАННЫМ ПОКАЗАНИЯМ

https://doi.org/10.14412/1995-4484-2011-576

Полный текст:

Список литературы

1. <div><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин. мед. 2005; 6: 8-12</p><p>Сигидин Я.А., Лукина Г.В. Биологическая терапия огии. М., 2007; 180 с.</p><p>Каратеев Д.Е. Современная медикаментозная терапия ревматоидного артрита. Леч. врач 2007; 2: 40-6.</p><p>Smolen J.S., Han C., Bala M. et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. Arthr Rheum 2005; 52(4): 1020-30.</p><p>Breedveld F., Weisman M., Kavanaugh A. et al. A multicenter, randomized, double- blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthr Rheum 2006; 54: 26-37.</p><p>Carswell E.A., Old L.J., Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci 1975; 72: 3666-70.</p><p>Helson L., Green S., Carswell E., Old L. Effect of tumour necrosis factor on cultured human melanoma cells. Nature 1975; 258(5537): 731-2.</p><p>Fiers W. in: Aggarwal В.В. and Vilcek J., eds. Tumor Necrosis Factor: Structure, Function, and Mechanism of Action. New York: Marcel Dekker, 1991.</p><p>Beutler В., Greenwald D., Hulmes J.D. et al. Identity of tumour necrosis factor and the macrophage-secreted factor cachectin. Nature 1985; 316(6028): 552-4.</p><p>Mannel D.N., Moore R.N., Mergenhagen S.E. Macrophages as a sourse of tumorocidal activity (tumor-necrozing factor). Infect Immun 1980; 30: 523-30.</p><p>Vassalli P. The pathophysiology of tumor necrosis factors. Annu Rev Immunol 1992; 10: 411-52.</p><p>Hohmann H.P., Remy R., Smith J. et al. Two different cell types have different major receptors for human TNF. J Biol Chem 1989; 264: 14927-34.</p><p>Hsu H., Xiong I., Goeddel D.V. The TNF receptor1-associated protein TRADD signals cell death NFkB activation. Cell 1995; 81: 495-504.</p><p>Malik S.T., Naylor M.S., East N. et al. Cells secreting tumour necrosis factor show enhanced metastasis in nude mice. Eur J Cancer 1990; 26: 1031-4.</p><p>Сигидин Я.А., Лукина Г.В. Препарат инфликсимаб в современной ревматологии. Consilium medicum 2005; 7: 118-21</p><p>Knight D.M., Trinh H., Le J. et al. Construction and initial characterisation of mouse-human chimeric monoclonal antibody to tumor necrosis factor-а antibody Mol Immunol 1993; 30: 1105-10.</p><p>Eissner G., Kolch W., Scheurich P. Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system. Cytokine Growth Factor Rev 2004; 15: 353-66.</p><p>Charles P., Elliott M.J., Davis D. et al. Regulation of Cytokines, Cytokine in Rheumatoid Arthritis Following Anti-TNF-{alpha} Therapy Inhibitors, and Acute-Phase Proteins. J Immunol 1999; 163: 1521-8.</p><p>Ehrenstein M.R., Evans J.G., Singh A. et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNF alpha therapy. J Exp Med 2004; 200: 277-85.</p><p>Valencia X., Stephens G., Goldbach- Mansky R. et al. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253-61.</p><p>. Souto-Carneiro M.M., Mahadevan V., Takada K. et al. Alterations in peripheral blood memory В cells in patients with active rheumatoid arthritis are dependent on the action of tumour necrosis factor. Arthr Res Ther 2009; 11: 84.</p><p>Справочник лекарственных средств Формулярного комитета. Изд. 4-е, доп. М.: Ньюдиамед, 2008; 721 с.</p><p>Белоусова Е.А., Морозова Н.А., Никитина Н.В. Инфликсимаб (Ремикейд) в лечении рефрактерных форм болезни Крона. Рус. мед. журн. 2005; 7(1): 28-32.</p><p>Клинические рекомендации. Ревматология. Под ред. Е.Л. Насонова. 2-е изд., испр. и доп. М.: ГЭОТАР-Медиа, 2010; 752 с.</p><p>Furst D., Keystone E., Fleischmann R. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009. Ann Rheum Dis 2010; 69: 2-29.</p><p>Муравьев Ю.В. Генно-инженерные биологические препараты в лечении АА-амилоидоза у больных ревматоидным артритом. Науч.-практич. ревматол. 2010; 2: 66-70.</p><p>Pettersson T., Konttinen Y.T., Maury C.P Treatment strategies for amyloid A amyloidosis. Expert Opin Pharmacother 2008; 9: 2117-28.</p><p>Elkayam O., Hawkins P.N., Lachmann H. et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthr Rheum 2002; 46: 2571-3.</p><p>Gottenberg J.E., Merle-Vincent F., Bentaberry F. et al. Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a follow-up report of tolerability and efficacy. Arthr Rheum 2009; 48: 2019-24.</p><p>Ortiz-Santamaria V., Valls-Roc M., Sanmarti M. et al. Treatment of secondary amyloidosis with infliximab. Arthr Rheum 2002; 46(Suppl): 71.</p><p>Tomero E., Carmona L., Gonzalez I. et al. Infliximab in secondary amyloidosis compli- cating inflammatory arthropathies. Arthr Rheum 2002; 46: 70.</p><p>Rheum 2002; 46: 70. Kuroda T., Wada Y., Kobayashi D. et al. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. J Rheumatol 2009; 36: 2409-15.</p><p>Keersmaekers T., Claes K., Kuypers D.R. et al. Long-term efficacy of infliximab treatment for AA-amyloidosis secondary to chronic inflammatory arthritis. Ann Rheum Dis 2009; 68: 759-61.</p><p>Jacquet A., Francois H., Frangie C. et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant 2009; 24: 3540-2.</p><p>Charles P.J., Smeenk R.J., De Jong J. et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. Arthr Rheum 2000; 43: 2383-90.</p><p>De Bandt M., Sibilia J., Le Loët X. et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. Arthr Res Ther 2005; 7: 545-51.</p><p>Wetter D.A., Davis M.D. Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic. Mayo Clin Proc 2009; 84: 979-84.</p><p>Aringer M., Graninger W.B., Steiner G., Smolen J.S. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study Arthr Rheum 2004; 50: 3161-9.</p><p>Matsumura R., Umemiya K., Sugiyama T. et al. Anti-tumor necrosis factor therapy in patients with dificult-to-treat lupus nephritis: a prospective series of nine patients. Clin Exp Rheumatol 2009; 27: 416-21.</p><p>Aringer M., Steiner G., Graninger W.B. et al. Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthr Rheum 2007; 56: 274-9.</p><p>Aringer M., Houssiau F., Gordon C. et al. Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009; 48: 1451-4.</p><p>Алекберова З.С., Танковский В.Э., Елонаков А.В. Применение инфликсимаба при болезни Бехчета (собственные наблюдения). Рус. мед. журн. 2005; 24: 1595-7.</p><p>Sfikakis P.P., Theodossiadis P.G., Katsiari C.G. et al. Effect of infliximab on sightthreatening panuveitis in Behcet's disease. Lancet 2001; 358: 295-6.</p><p>Yamada Y., Sugita S., Tanaka H. et al. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behcet disease. Br J Ophthalmol 2010; 94: 284-8.</p><p>Sugita S., Yamada Y., Mochizuki M. Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease. Br J Ophthalmol 2010; 27.</p><p>Pipitone N., Olivieri I., Padula A. et al. Infliximab for the treatment of Neuro-Behcet's disease: a case series and review of the literature. Arthr Rheum 2008; 15(59): 285-90.</p><p>Abalos-Medina G.M., Sanchez-Cano D., Ruiz-Villaverde G., et al. Successful use of infliximab in a patient with neuro-Behcet's disease. Int J Rheum Dis 2009; 12: 264-6.</p><p>Ju J.H., Kwok S.K., Seo S.H. et al. Successful treatment of life-threatening intestinal ulcer in Behcet's disease with infliximab: rapid healing of Behcet's ulcer with infliximab. Clin Rheumatol 2007; 26: 1383-5.</p><p>Kasugai C., Watanabe D., Mizutani K. et al. Infliximab treatment of severe genital ulcers associated with Behcet disease. J Am Acad Dermatol 2010; 62: 162-4.</p><p>Lamprecht P., Voswinkel J., Lilienthal T. et al. Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis. Rheumatology (Oxford) 2002; 41: 1303-7.</p><p>Gause A.M., Arbach O., Reinhold-Keller E. et al. Induction of remission with infliximab in active generalized Wegener's granulomatosis is effective but complicated by severe infections [abstract]. ACR Congress. Orlando, 2003; 450.</p><p>Booth A., Harper L., Hammad T. et al. Prospective study of TNF-alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J Am Soc Nephrol 2004; 15: 717-21.</p><p>Laurino S., Chaudhry A., Booth A. et al. Prospective study of TNF{alpha} blockade with adalimumab in ANCA-associated systemic vasculitis with renal involvement. Nephrol Dial Transplant 2010; Apr 5 [Epub ahead of print].</p><p>The Wegener's Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-61.</p><p>Efthimiou P., Schwartzman S., Kagen L.J. Possible role for tumour necrosis factor inhibitors in the treatment of resistant dermatomyositis and polymyositis: a retrospective study of eight patients. Ann Rheum Dis 2006; 65: 1233-6.</p><p>Riley P., McCann L.J., Maillard S.M. et al. Effectiveness of infliximab in the treatment of refractory juvenile dermatomyositis with calcinosis. Rheumatology (Oxford) 2008; 47: 877-80.</p><p>Dastmalchi M., Grundtman C., Alexanderson H. et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-7.</p><p>Carter J.D. Treatment of relapsing polychondritis with a TNF antagonist. J Rheumatol 2005; 32: 1413.</p><p>Ramos-Casals M., Brito-Zeron P., Munoz S., Soto M.J. BIOGEAS STUDY Group. A sys- tematic review of the off-label use of biological therapies in systemic autoimmune diseases. Medicine (Baltimore) 2008; 87: 345-64.</p><p>Насонов Е.Л., Козлов Р.С., Якушин С.Б. Инфекционные осложнения блокаторами фактора некроза опухоли: предупрежден -значит вооружен. Клин. микробиол. антимикроб. химиотер. 2006; 8(4): 314-24.</p><p>Poli G., Fauci A.S. The effect of cytokines and pharmacologic agents on chronic HIV infection. AIDS Res Hum Retroviruses 1992; 8: 191-7.</p><p>Poli G., Fauci A.S. Cytokine modulation of HIV expression. Semin Immunol 1993; 5: 165-73.</p><p>Grau G.E., Piguet P.F., Vassalli P., Lambert P.H. Tumor-necrosis factor and other cytokines in cerebral malaria: experimental and clinical data. Immunol Rev 1989; 112: 49-70.</p><p>Knight D.M., Trinh H., Le J. et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody Mol Immunol 1993; 30: 1443-53.</p><p>Maini R.N., Elliott M.J., Brennan F.M., Feldmann M. Beneficial effects of tumour necrosis factor-alpha (TNF-alpha) blockade in rheumatoid arthritis (RA). Clin Exp Immunol 1995; 101: 207-12.</p><p>Maini R.N., Elliott M., Brennan F.M. et al. Targeting TNF alpha for the therapy of rheumatoid arthritis. Clin Exp Rheumatol 1994; 12(Suppl. 11): 63-6.</p><p>Targan S.R., van Deventer S.J.H. et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease. N Engl J Med 1997; 337: 1029-35.</p><p>Fautrel В., Cherin P. Value of anti-TNF-alpha molecules in inflammatory and infectious diseases. Rev Med Interne 2000; 21: 872-88.</p><p>Calandra T., Baumgartner J.D., Glauser M.P. Anti-lipopolysaccharide and antitumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock. Prog Clin Biol Res 1991; 367: 141-59.</p><p>Pennington J.E. Therapy with antibody to tumor necrosis factor in sepsis. Clin Infect Dis 1993; 17(Suppl. 2): 515-9.</p><p>Fisher C.J. Jr., Opal S.M., Dhainaut J.F. et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group. Crit Care Med 1993; 21: 318-27</p><p>Abraham E., Wunderink R., Silverman H. et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273: 934-41.</p><p>M.A., Plank L.D., Connolly A.B. et al. Effect of a chimeric antibody to tumor necrosis factor-alpha on cytokine and physiologic responses in patients with severe sepsis - a randomized, clinical trial. Crit Care Med 1998; 26: 1650-9.</p><p>Balkwill F.R., Charles K.A., Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 211-7.</p><p>Moore R.J., Owens D.M., Stamp G. et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med 1999; 5: 828-31.</p><p>Szlosarek P., Charles K.A., Balkwill F.R. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42: 745-50.</p><p>Mantovani G., Maccio A., Madeddu C. et al. Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. Int J Cancer 2002; 9: 84-91.</p><p>Szlosarek P.W., Grimshaw M.J., Kulbe H. et al. Expression and regulation of tumor necrosis factor alpha in normal and malignant ovarian epithelium. Mol Cancer Ther 2006; 5: 382-90.</p><p>Miles D.W., Happerfield L.C., Naylor M.S. et al. Expression of tumour necrosis factor (TNF alpha) and its receptors in benign and malignant breast tissue. Int J Cancer 1994; 56: 777-82.</p><p>Scheurich P., Ucer U., Kronke M., Pfizenmaier K. Quantification and characterization of high-affinity membrane receptors for tumor necrosis factor on human leukemic cell lines. Int J Cancer 1986; 38: 127-33.</p><p>Pedersen I.M., Otero D., Kao E. et al. Onco-miR-155 targets SHIP1 to promote TNFalpha-dependent growth of В cell lymphomas. EMBO Mol Med 2009; 1: 288-95.</p><p>Harrison M.L., Obermueller E., Maisey N.R. et al. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 2007; 10; 25: 4542-9.</p><p>Brown E.R., Charles K.A., Hoare S.A. et al. A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 2008; 19: 1340-6.</p><p>Wiedenmann В., Mafertheiner P., Friess H. et al. A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia. J Support Oncol 2008; 6: 18-25.</p><p>Jatoi A., Ritter H.L., Dueck A. et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer 2010; 68: 234-9.</p><p>Sethi G., Sung В., Kunnumakkara A.B., Aggarwal В.В. Targeting TNF for Treatment of Cancer and Autoimmunity. Adv Exp Med Biol 2009; 647: 37-51.</p><p>Sfikakis P.P. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. Curr Dir Autoimmun 2010; 11: 180-210.</p><p>Каратеев Д.Е. Низкая активность и ремиссия при ревматоидном артрите: клинические, иммунологические и морфологические аспекты. Науч.-практич. ревматол. 2009; 5: 4-12.</p></div><br />


Для цитирования:


Karateyev D.E., Sinelnikova T.G., Litvitsky P.F. БОРЬБА С МНОГОЛИКИМ КАХЕКТИНОМ (ОПЫТ ПРИМЕНЕНИЯ ИНФЛИКСИМАБА ПО НЕЗАРЕГИСТРИРОВАННЫМ ПОКАЗАНИЯМ. Научно-практическая ревматология. 2011;49(3):75-81. https://doi.org/10.14412/1995-4484-2011-576

For citation:


Karateyev D.E., Sinelnikova T.G., Litvitsky P.F. To combat with multifaceted cachectin (experience with infliximab used for unregistered indications. Rheumatology Science and Practice. 2011;49(3):75-81. (In Russ.) https://doi.org/10.14412/1995-4484-2011-576

Просмотров: 496


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)